GlassScriptPhysician profile
Miranda Mccoy
NPI 1043770100
$3,715.33
in general payments reported to CMS, 2019-2025
27 companies · $1,468 in 2025
The $1,468 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.34 · 2020: $70.40 · 2021: $14.88 · 2022: $325 · 2023: $856 · 2024: $936 · 2025: $1,468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,259.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $475.60 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $407.77 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $340.28 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $338.01 | 2019-2025 | |
| Dexcom, INC. | $291.88 | 2023-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $258.48 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $195.12 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $182.92 | 2025 | Caplyta |
| Abbvie INC. | $180.78 | 2022-2025 | |
| Inari Medical, INC. | $151.03 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Bayer Healthcare Pharmaceuticals INC. | $129.60 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.77 | 2022-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $113.79 | 2023-2025 | |
| Amgen INC. | $81.06 | 2023-2024 | Otezla, Repatha |
| Axsome Therapeutics, INC. | $69.39 | 2025 | Symbravo, Auvelity |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $62.48 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $57.63 | 2022 | |
| Sanofi-Aventis U.S. LLC | $46.56 | 2023-2025 | |
| Medtronic, INC. | $38.16 | 2023-2024 | Intellis Adaptivestim |
| Otsuka America Pharmaceutical, INC. | $28.57 | 2024 | Rexulti |
| Abbott Laboratories | $24.71 | 2025 | Eterna |
| Shield Therapeutics INC | $24.18 | 2025 | |
| Boston Scientific Corporation | $21.07 | 2025 | Wavewriter Alpha Prime 16 |
| Sumitomo Pharma America, INC. | $20.43 | 2024 | Gemtesa |
| Shire North American Group INC | $20.17 | 2019 | |
| Alexion Pharmaceuticals, INC. | $16.97 | 2024 | Strensiq |
| Esperion Therapeutics, INC. | $16.92 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miranda Mccoy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.